Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Price, Quote, News and Overview

NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD

3.53  +0.33 (+10.31%)

After market: 3.5 -0.03 (-0.85%)

MYNZ Quote, Performance and Key Statistics

MAINZ BIOMED NV

NASDAQ:MYNZ (4/25/2025, 8:25:18 PM)

After market: 3.5 -0.03 (-0.85%)

3.53

+0.33 (+10.31%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High40.4
52 Week Low2.65
Market Cap8.19M
Shares2.32M
Float2.24M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO11-04 2021-11-04


MYNZ short term performance overview.The bars show the price performance of MYNZ in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

MYNZ long term performance overview.The bars show the price performance of MYNZ in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of MYNZ is 3.53 USD. In the past month the price decreased by -11.04%. In the past year, price decreased by -89.21%.

MAINZ BIOMED NV / MYNZ Daily stock chart

MYNZ Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About MYNZ

Company Profile

MYNZ logo image Mainz Biomed NV is a molecular genetics cancer diagnostic company. The company is headquartered in Mainz, Hessen and currently employs 19 full-time employees. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Company Info

MAINZ BIOMED NV

Sirius Gutenberg Park, Robert-Koch-Strasse 50

MAINZ HESSEN DE

Employees: 68

Company Website: https://www.mainzbiomed.com/

Investor Relations: https://mainzbiomed.com/investors/

Phone: 4961315542860

MAINZ BIOMED NV / MYNZ FAQ

What is the stock price of MAINZ BIOMED NV today?

The current stock price of MYNZ is 3.53 USD. The price increased by 10.31% in the last trading session.


What is the ticker symbol for MAINZ BIOMED NV stock?

The exchange symbol of MAINZ BIOMED NV is MYNZ and it is listed on the Nasdaq exchange.


On which exchange is MYNZ stock listed?

MYNZ stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MAINZ BIOMED NV stock?

8 analysts have analysed MYNZ and the average price target is 14.28 USD. This implies a price increase of 304.53% is expected in the next year compared to the current price of 3.53. Check the MAINZ BIOMED NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MAINZ BIOMED NV worth?

MAINZ BIOMED NV (MYNZ) has a market capitalization of 8.19M USD. This makes MYNZ a Nano Cap stock.


How many employees does MAINZ BIOMED NV have?

MAINZ BIOMED NV (MYNZ) currently has 68 employees.


What are the support and resistance levels for MAINZ BIOMED NV (MYNZ) stock?

MAINZ BIOMED NV (MYNZ) has a support level at 3.26 and a resistance level at 3.54. Check the full technical report for a detailed analysis of MYNZ support and resistance levels.


Is MAINZ BIOMED NV (MYNZ) expected to grow?

The Revenue of MAINZ BIOMED NV (MYNZ) is expected to grow by 18.01% in the next year. Check the estimates tab for more information on the MYNZ EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MAINZ BIOMED NV (MYNZ) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MAINZ BIOMED NV (MYNZ) stock pay dividends?

MYNZ does not pay a dividend.


What is the Price/Earnings (PE) ratio of MAINZ BIOMED NV (MYNZ)?

MAINZ BIOMED NV (MYNZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-22.36).


What is the Short Interest ratio of MAINZ BIOMED NV (MYNZ) stock?

The outstanding short interest for MAINZ BIOMED NV (MYNZ) is 6.12% of its float. Check the ownership tab for more information on the MYNZ short interest.


MYNZ Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

MYNZ Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MYNZ. Both the profitability and financial health of MYNZ have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MYNZ Financial Highlights

Over the last trailing twelve months MYNZ reported a non-GAAP Earnings per Share(EPS) of -22.36. The EPS increased by 65.47% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -163.55%
ROE -358.07%
Debt/Equity 0.14
Chartmill High Growth Momentum
EPS Q2Q%28.99%
Sales Q2Q%74.39%
EPS 1Y (TTM)65.47%
Revenue 1Y (TTM)-0.17%

MYNZ Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to MYNZ. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 61.96% and a revenue growth 18.01% for MYNZ


Ownership
Inst Owners11.06%
Ins Owners4.07%
Short Float %6.12%
Short Ratio0.8
Analysts
Analysts80
Price Target14.28 (304.53%)
EPS Next Y61.96%
Revenue Next Year18.01%